Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Denise Connolly

Email
Center AffiliationsMolecular Therapeutics

Publications (45) (print view)

paginate
Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther. 2019 Mar 30;20(7):1035-45.   PMCID: PMC6606007
Hoyer PB, Rice PF, Howard CC, Koevary JW, Dominguez Cooks JP, Hutchens GV, Chambers SK, Craig ZR, Connolly DC, Barton JK. Comparison of Reproductive Function in Female TgMISIIR-TAg Transgenic and Wildtype C57BL/6 Mice. Comparative medicine. 2019 Feb;69(1):16-21.   PMCID: PMC6382048
Kleinschmidt EG, Miller NL, Ozmadenci D, Tancioni I, Osterman CD, Barrie AM, Taylor KN, Ye A, Jiang S, Connolly DC, Stupack DG, Schlaepfer DD. Rgnef promotes ovarian tumor progression and confers protection from oxidative stress. Oncogene. 2019 Jul 15;.
Wang Y, Sessine MS, Zhai Y, Tipton C, McCool K, Kuick R, Connolly DC, Fearon ER, Cho KR. Lineage tracing suggests that ovarian endosalpingiosis does not result from escape of oviductal epithelium. The Journal of pathology. 2019 May 27;.
Gabbasov R, Xiao F, Howe CG, Bickel LE, O'Brien SW, Benrubi D, Do TV, Zhou Y, Nicolas E, Cai KQ, Litwin S, Seo S, Golemis EA, Connolly DC. NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene. 2018 Aug;37(35):4854-70.   PMCID: PMC6119087
Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, O'Brien SW, Litwin S, Davis B, Connolly DC, Coleman TP. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers. Cancer Biol Ther. 2018 Jul 03;19(7):554-64.   PMCID: PMC5989790
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Oct;562(7728):526-31.   PMCID: PMC6280667
Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Wickramasinghe J, Nguyen JM, O'Brien SW, Gumireddy K, Huang Q, Cadungog MG, Connolly DC, Tchou J, Curiel TJ, Conejo-Garcia JR. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res. 2017 Jan 15;23(2):441-53.   PMCID: PMC5241180
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep. 2016 Aug 02;16(5):1273-86.   PMCID: PMC4972668
Melikechi N, Markushin Y, Connolly DC, Lasue J, Ewusi-Annan E, Makrogiannis S. Age-specific discrimination of blood plasma samples of healthy and ovarian cancer prone mice using laser-induced breakdown spectroscopy. Spectrochimica Acta - Part B Atomic Spectroscopy. 2016 Sep;123:33-41.
Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmana J, Serra V, Johnson N. The BRCA1-Delta11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016 May;76(9):2778-90.   PMCID: PMC4874568
Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, Van Der Gulden H, Van Der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, K'Con F, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N. The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 2016 Jan;76(9):2778-90.
Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu R, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Molecular Cancer Therapeutics. 2015 Apr;14(4):1035-47.   PMCID: 4394029
Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth. Mol Cancer Ther. 2015 Apr;14(4):1035-47.   PMCID: PMC4394029
Markushin Y, Sivakumar P, Connolly D, Melikechi N. Tag-femtosecond laser-induced breakdown spectroscopy for the sensitive detection of cancer antigen 125 in blood plasma. Anal Bioanal Chem. 2015 Mar;407(7):1849-55.
Sakalar C, Mazumder S, Johnson JM, Altuntas CZ, Jaini R, Aguilar R, Naga Prasad SV, Connolly DC, Tuohy VK. Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Mullerian Hormone Receptor II. Journal of immunology research. 2015 Jan;2015:630287.   PMCID: PMC4651663
Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2014 Jan 30;33(5):539-49.   PMCID: PMC3640671
Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecologic Oncology. 2014 Jul;134(1):104-11.   PMCID: PMC4065804
Liu HQ, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC. Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer. Clinical Cancer Research. 2013 Sep;19(18):5053-67.   PMCID: PMC 3778161
Hensley HH, Roder NA, O'Brien SW, Bickel LE, Xiao F, Litwin S, Connolly DC. Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice. Neoplasia (New York, NY). 2012 Jun;14(6):451-62.   PMCID: PMC3394188
Lara H, Wang YH, Beltran AS, Juarez-Moreno K, Yuan XN, Kato S, Leisewitz AV, Fredes MC, Licea AF, Connolly DC, Huang L, Blancafort P. Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. Journal of Biological Chemistry. 2012 Aug;287(35):29873-86.   PMCID: PMC3436144
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 2012 Mar 08;31(10):1217-27.   PMCID: PMC3204164
Rozmiarek H, Connolly DC. Response to Protocol Review Scenario: Specify all medications. Lab Anim (NY). 2011 Mar;40(3):66-7.   PMCID: not NIH funded
Deng S, Yang XJ, Lassus H, Liang S, Kaur S, Ye QR, Li CS, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang YC, Montone K, Butzow R, Coukos G, Zhang L. Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. Plos One. 2010 Apr;5(4):E10277.   PMCID: PMCID: PMC2858084
Williams RM, Flesken-Nikitin A, Ellenson LH, Connolly DC, Hamilton TC, Nikitin AY, Zipfel WR. Strategies for High-Resolution Imaging of Epithelial Ovarian Cancer by Laparoscopic Nonlinear Microscopy. Translational Oncology. 2010 Jun;3(3):181-94.   PMCID: PMCID: PMC2887648
Connolly DC. Animal models of ovarian cancer. Cancer Treat Res. 2009 Jan;149:353-91.
Connolly DC, Hensley HH. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. Curr Protoc Pharmacol. 2009 Jun;45:14 12 1-14 12 26.   PMCID: PMC2904083
Izumchenko E, Singh MK, Plotnikova OV, Tikhmyanova N, Little JL, Serebriiskii IG, Seo S, Kurokawa M, Egleston BL, Klein-Szanto A, Pugacheva EN, Hardy RR, Wolfson M, Connolly DC, Golemis EA. NEDD9 Promotes Oncogenic Signaling in Mammary Tumor Development. Cancer Research. 2009 Sep;69(18):7198-206.   PMCID: PMC2768619
Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One. 2009 Jan;4(12):e8404.   PMCID: 2796165
Choi YS, Hoory T, Monie A, Wu A, Connolly D, Hung CF. alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors. Vaccine. 2008 Oct;26(46):5855-63.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR. RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer. Cancer Res. 2007 Mar 15;67(6):2408-13.
Disis ML, Rivkin SE, Baron A, Markman M, Connolly D, Ueland F, Kohn E, Trimble E, Berek JS. Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2006 Mar;16(2):463-9.
Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2006 Nov;103(46):17426-31.
Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. CLINICAL CANCER RESEARCH. 2006 Mar;12(5):1593-8.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescut DM, Connolly D, Foster R, Dombkowski D, Preffer F, MacLaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006 Jul;103(30):11154-9.
Danielsen AJ, Christensen TA, Lovejoy CA, Adelsman MA, Connolly DC, Maihle NJ. Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation. Experimental Cell Research. 2004 Jun 10;296(2):285-93.
Nikitin AY, Connolly DC, Hamilton TC. Pathology of ovarian neoplasms in genetically modified mice. Comparative medicine. 2004 Feb;54(1):26-8.
Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu XX, Hamilton TC. Focus on epithelial ovarian cancer. Cancer cell. 2004 Jan;5(1):19-24.
Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female Mice Chimeric for Expression of the Simian Virus 40 TAg under Control of the MISIIR Promoter Develop Epithelial Ovarian Cancer. Cancer Res. 2003 Mar 15;63(6):1389-97.
Hamilton TC, Connolly DC, Nikitin AY, Garson K, Vanderhyden BC. Translational research in ovarian cancer: a must. Int J Gynecol Cancer. 2003 Jan;13:1-11.
Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer-specific gene expression by the survivin promoter. Journal of the National Cancer Institute. 2002 Apr 03;94(7):522-8.
Cvetkovic D, Connolly DC, Hamilton TC. Molecular biology and molecular genetics of ovarian, primary peritoneal, and fallopian tube cancer (section 3, chapter 28). In: Gershenson, Gore, McGuire, Quinn, Thomas, editors. Gynecologic Cancer: Controversies in Management. Philadelphia: Elsevier Science; 2002.
Selvakumaran M, Bao R, Crijns AP, Connolly DC, Weinstein JK, Hamilton TC. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res. 2001 Feb 15;61(4):1291-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Denise Connolly Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Wednesday, September 04, 2019